DAVY VIEW

Amryt has announced positive pre-clinical results for its gene therapy AP103. This is another indication of the progression being made in Amryt’s Epidermolysis Bullosa (EB) franchise, one of its three pillars of growth. This follows the positive recommendation on January 4th that AP101 should continue its Phase III trial. AP103 is targeting a particularly severe form of EB that could be complementary to AP101 over time. The AP103 gene therapy platform also holds potential for other genetic skin disorders. Phase I studies for AP103 are expected to begin in 2019.